ctDNA test for tracking cancer after treatment
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial uses a blood test to find tiny bits of tumor DNA after treatment. It helps doctors see if any cancer remains, which could guide next steps for people with esophageal, stomach, or pancreatic cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be willing to join the study and sign a consent form.
- You have esophageal, stomach, or pancreatic cancer that has not spread far (stage 0 to 2), or is locally advanced but can be removed with surgery, or has spread but you've had 1 to 3 rounds of treatment.
- If your cancer is locally advanced, you must have had chemotherapy or chemoradiation before surgery.
- If your cancer has spread, you must have had 1 to 3 types of treatment already.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether a special blood test (ctDNA) can detect tiny amounts of pancreatic cancer left after surgery. It may help doctors monitor who is at higher risk of cancer coming back, so they can tailor follow-up and treatment timing.
This study checks if a blood test can find leftover cancer DNA after stomach cancer surgery. It helps doctors know if more treatment is needed.
This study looks at tiny amounts of cancer DNA left in the blood after surgery for solid tumors. It aims to understand how well surgery works and if more treatment is needed.
This study uses special blood tests to detect cancer DNA and help doctors decide the best treatment plan for gastric cancer. The goal is to improve outcomes by personalizing therapy based on how your cancer responds.
This trial is for people who had surgery for pancreatic cancer and are now deciding on maintenance therapy. A special blood test (ctDNA) may help doctors choose the best follow-up treatment to prevent the cancer from coming back.
This trial tests if adding extra local treatments (like surgery or radiation) to usual care can improve outcomes for people with certain advanced digestive cancers that have spread to a limited number of sites. You may be eligible if your cancer has responded well to at least 4 months of therapy and your ctDNA (a sign of cancer in the blood) is undetectable.
Hear when a new Esophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.